02/19/2013
[ACCESSWIRE]
Microbix Biosystems Inc. focuses on developing and commercializing biological products and technologies through leveraging its Core Base Business of developing infectious disease antigens (virology) for sale to large diagnostic kit manufacturers.
The Company has reported Q1/F2013 results, and has provided an update on its product pipeline – namely, Kinlytic™ (Urokinase), VIRUSMAX™, and LumiSort™. eResearch notes that Bioniche is now on the cusp of reaping the benefits of years of development.
Read more here: http://eresearch.ca/_report/MBX_021913-B.pdf
eResearch is a primary source for professional investment research, focused primarily on small- and mid-cap companies. Our research and analysis is of institutional quality, and has the potential for reaching millions of global investors through our extensive electronic distribution network.
eResearch posts all its reports and articles on its website, eresearch.ca, and subscription is FREE.
Contact:
eResearch: Bob Weir, CFA, Director of Research
Telephone: (416) 703-6258 Ext 221; E-mail: bweir@eresearch.ca
Leave a comment...
*